Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track (CRSP)

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the stock's prospects.